Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.

Similar presentations


Presentation on theme: "Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline."— Presentation transcript:

1 Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Kohli A, et al. 21 st CROI. 2014:Abstract 27LB.

2 Hepatitis web study Source: Kohli A, et al. 21 st CROI. 2014:Abstract 27LB. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIH SYNERGY Trial: Features

3 Hepatitis web study Source: Kohli A, et al. 21 st CROI. 2014:Abstract 27LB. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIH SYNERGY Trial: Features LDV-SOF + GS-9669 Treatment Naïve All stages fibrosis n = 20 LDV-SOF + GS-9451 n = 20 LDV-SOF Treatment Naïve Cirrhosis excluded Abbreviations: LDV-SOF= ledipasvir-sofosbuvir Drug Dosing Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once daily GS-9669: 500 mg once daily GS-9451: 80 mg once daily Week 02461218 SVR12

4 Hepatitis web study Source: Kohli A, et al. 21 st CROI. 2014:Abstract 27LB. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIH SYNERGY Trial: Participants Baseline Characteristic LDV-SOF x 12 weeks (n=20) LDV-SOF + GS-9669 x 6 weeks (n=20) LDV-SOF + GS-9451 x 6 weeks (n=20) Age, mean5754 Male, %706580 Black, %809590 HCV genotype, % 1A 1B 55 45 70 30 85 15 IL28B CT/TT, %759075 Advanced fibrosis, % Knodell score 3 Knodell score 4 25 15 25 0 25 0

5 Hepatitis web study Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIH SYNERGY Trial: Features NIH SYNERGY: SVR 12 by Treatment Regimen Source: Kohli A, et al. 21 st CROI. 2014:Abstract 27LB. 20/2019/2020/20

6 Hepatitis web study Hepatitis web study This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online www.hepatitisc.uw.edu www.hepatitisc.uw.edu Hepatitis Web Study http://depts.washington.edu/hepstudy/ http://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online www.hepatitisc.uw.edu www.hepatitisc.uw.edu Hepatitis Web Study http://depts.washington.edu/hepstudy/ http://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.


Download ppt "Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline."

Similar presentations


Ads by Google